Innovations in Oncology Drug Discovery, Development & Delivery

Webinar: December 1 & December 10, 2009.
Every day academics, diagnostic developers, biotech and pharma companies get closer to scientific breakthroughs in technology and methods that are applicable to oncology treatments. Given the sheer volume of such discoveries, it is becoming increasingly difficult for potential stakeholders to become aware of these advances and remain updated. Emerging technology in areas such as nanosciences, medical imaging, bioinformatics, and particle engineering have been combined with medical biology to give rise to a new generation of oncology therapies. Not only have researchers been able to make discoveries that can exploit the cellular and genomic make up of cancer cells, but they are also pioneering methods to deliver such treatments precisely to these cells.

This webinar series will give viewers a chance to hear about cutting edge research from the minds that brought it to life, all without leaving the home or office. Hear first-hand accounts from both world-class institutions as well as lesser-known enterprises from around the world. Some of the presenters will be publicly talking about their work for the first time while others will be presenting the most recent updates of their work. Learn about the latest gene, cell, and molecular therapies and the novel methods that can be used to deliver them directly to the target site. NextLevel Pharma's webinar series will bring this revolutionary research and technology closer to the industry via our webinar platform which allows the viewer to interact with the innovators themselves.

Why Participate?

  • Stay informed of the latest technologies in oncology drug research from some of the world’s leading scientists and researchers from the luxury of your own office
  • Expand your network and create alliances with oncology R&D experts
  • Gain insight as some of today’s more pioneering researchers present their innovative work which is rarely made public
  • Learn how to accelerate your R&D using cutting-edge platform technologies that are applicable to your portfolio
  • Identify and understand how to use these new approaches and apply them to existing molecules to increase safety and efficacy

Who will benefit

  • Pharmaceutical, Biotech, Diagnostic & Academic research organisations
  • CEOs / Vice-Presidents / Heads / CSOs / Managers / Professors and Scientists involved in: Discovery and platform technology, business development, in-licensing, molecular diagnostics, pharmacogenomics/genetics/proteomics, translational medicine, clinical science and development, molecular imaging, pre-clinical development, modeling and simulation, pharmacology, pharmacokinetics/pharmacodynamics

For further information and registration, please visit:
http://www.nextlevelpharma.com/events/view/innovations_in_oncology_drug_discovery_development_delivery

About NextLevel Pharma
NextLevel Pharma is a leading, global strategic business information and opportunity provider for the international life sciences industry.

NextLevel Pharma brings the life sciences industry closer together and organise intelligent conferences and events for industry, personalised meetings for individual companies, as well as tailored partnering services.

For more information, please visit www.nextlevelpharma.com.

Most Popular Now

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

NIH launches clinical trial of mRNA Nipah virus va…

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an inv...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...